Novartis news from FierceBiotech
NewsNexMed tanks after Novartis stalls on fungus drug
Shares of NexMed tanked after the company announced late Tuesday that Novartis would not be submitting an NDA for their partnered nail fungus therapy "at this time." According to NexMed, Novartis was Read more...
EMEA issues host of decisions
The EMEA's Committee for Medicinal Products for Human Use (CHMP) has been busy. The drug regulator released a host of decisions today, so here's the round-up:
The Committee for Medicinal Products in Read more...
Novartis and Alcon - Billion-dollar deals
Who: NovartisWith: AlconWhat: $39B buyout Scoop: Diversification was the name of the game as Novartis pledged $39 billion for the eye care company Alcon. Novartis bought a 25 percent stake in Alcon Read more...
Novartis buying Speedel for $880 million
Switzerland's Novartis has scooped up a majority of the shares of Speedel and plans to swiftly complete the purchase of all its stock in a deal valued at $880 million. At 130 francs per share, Read more...
DPP-4 inhibitors get spotlight at ADA meeting
Researchers are unveiling positive data at the American Diabetes Association's meeting for new DPP-4 inhibitors for diabetes. Takeda is the latest, demonstrating that its alogliptin can control blood Read more...
Novartis eyes vaccines with Protez purchase
Novartis is shelling out $400 million for antibiotics developer Protez Pharmaceuticals. Protez gets for $100 million up front and up to $300 million more if Protez's new broad-spectrum antibiotic is Read more...
ALSO NOTED: Acorda shares soar; Lexicon wins fast track; NIH grants $533N in research funds; and much more...
> News yesterday that Acorda Therapeutics' experimental MS drug helped patients walk better sent its shares up 27 percent. Read more...
SPOTLIGHT: Antisoma gets $25M milestone from Novartis
Antisoma has received a $25 million milestone payment from Novartis, triggered by the recent initiation of a phase III trial of ASA404 in non-small cell lung cancer. Read more...
Merck's osteoporosis drug performs in Phase II
Merck's experimental osteoporosis drug odanacatib turned in positive results in a Phase II trial. The drug reduced measures of bone turnover (breakdown and rebuilding of bone) in women with breast Read more...
Novartis restructures its development strategy
Novartis CEO Daniel Vasella (photo) tells the Wall Street Journal that he knew Novartis had become too big and too Read more...
| Press ReleasesNew data show Menveo to be the first quadrivalent meningococcal vaccine to provide immunogenicity in infants New data show Menveo to be the first quadrivalent meningococcal vaccine to provide immunogenicity in infants Data in JAMA show Menveo may provide infants protection against four of the most common Read more... PRESS RELEASE: Novartis launches strategic initiative to improve competitiveness in a changing healthcare environmenT Novartis launches strategic initiative to improve competitiveness in a dynamically changing healthcare environment "Forward" to simplify organizational structures, accelerate and Read more... PRESS RELEASE: Novartis further strengthens biologics capabilities in expansion of MorphoSys collaboration Novartis further strengthens biologics capabilities in expansion of MorphoSys collaboration Collaboration efforts will focus on the discovery and optimization of antibodies against a significant Read more... PRESS RELEASE: Tasigna gains European approval for patients with a life-threatening form of leukemia who are resistant or intol Tasigna® gains European approval for patients with a life-threatening form of leukemia who are resistant or intolerant to existing therapies Tasigna produced response in 49% of patients with Read more... PRESS RELEASE: Antisoma Shares Slide as Novartis Corporation (NVS) Sets up Avastin Fight Antisoma Shares Slide as Novartis Corporation Sets up Avastin Fight LONDON--Nov 20, 2007 -- ASA404 phase III lung cancer trial to include broader range of patients London, UK: 20 November 2007 - Read more... |
Get more Novartis coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets